KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EBT (2016 - 2025)

Sarepta Therapeutics has reported EBT over the past 15 years, most recently at $357.4 million for Q4 2025.

  • Quarterly results put EBT at $357.4 million for Q4 2025, up 108.1% from a year ago — trailing twelve months through Dec 2025 was -$66.5 million (down 125.51% YoY), and the annual figure for FY2025 was -$66.5 million, down 125.51%.
  • EBT for Q4 2025 was $357.4 million at Sarepta Therapeutics, up from -$194.0 million in the prior quarter.
  • Over the last five years, EBT for SRPT hit a ceiling of $357.4 million in Q4 2025 and a floor of -$512.7 million in Q1 2023.
  • Median EBT over the past 5 years was -$23.9 million (2023), compared with a mean of -$26.5 million.
  • Peak annual rise in EBT hit 1031.6% in 2025, while the deepest fall reached 1025.3% in 2025.
  • Sarepta Therapeutics' EBT stood at $249.4 million in 2021, then crashed by 39.83% to $150.1 million in 2022, then surged by 114.43% to $321.8 million in 2023, then tumbled by 46.63% to $171.7 million in 2024, then surged by 108.1% to $357.4 million in 2025.
  • The last three reported values for EBT were $357.4 million (Q4 2025), -$194.0 million (Q3 2025), and $153.6 million (Q2 2025) per Business Quant data.